3[6]Garcia - Fernandez, N; Lavilla, FJ; Rocha, E; Purroy, A. Haemostatic changes in systemic inflammatory response syndrome during continuous renal replacement therapy. Journal of Nephrology, 2000, 13, (4): 282 -285
4Taskesen F, Atikanoglu Z, Uslukaya O, et al. Laparoscopic sal- vage for malfunctioning of peritoneal dialysis catheters[J]. Miner- va Chir, 2012,67(6) :505-509.
5Cabarkapa V, Djeri ~ M, Stosi ~ Z. Evaluation of lipid parameters and bioindices in patients with different stages of chronic renal fail- ure[J]. Adv Petit Dial, 2012,69( 11 ) :961-966.
6Ohashi Y, Kansal S, Schreiber M Jr. Frequency of puncture holes in peritoneal dialysis catheters related to the beta cap adapter[ J]. Adv Petit Dial, 2012,28( 11 ) :131-133.
7Hirakata H, Nitta K, Inaba M, et al. Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis [J]. Ther Apher Dial, 2012,16 (5) :387-435.
8安藤康宏他[J].透析会志,1985,18(7):173.
9Katzarski KS, Charra B, Luik A J, et al. Fluid state and blood pre- ssurecontrol in patients treated with long and short haemodialysis [ J]. Nephrol Dial Transplant, 1999,14(22) :369-375.
10Osajima A, Okazaki M, Kato H, et al. Clinical significance of na- triunetic peptides" and cyclicy GMP in hemodialysis patients with coronary artery disease [ J ]. Am J Nephrol, 2001,21 ( 2 ) : 112- 119.
